Bevacizumab in the Radiation Treatment of Recurrent Malignant Glioma

Status Completed

Clinical Trial Summary

This is a pilot study. The goal of this study is to test whether Bevacizumab is safe enough in patients with brain tumors so that a larger study can be conducted. This study will also give us some information about whether the combination of Bevacizumab and radiation has potential to become an effective treatment for regrowing brain tumors.

Bevacizumab is an experimental drug that blocks a molecule called VEGF that is found in high amounts in malignant gliomas. VEGF promotes the growth of blood vessels that bring nutrients to tumor cells. In studies with laboratory animals, Bevacizumab slowed the growth of several different types of human cancer cells by blocking the effects of VEGF. There is also evidence that Bevacizumab enhances the effects of radiation on tumor cell

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00595322
Study type	Interventional
Source	Memorial Sloan Kettering Cancer Center
Contact
Status	Completed
Phase	N/A
Start date	December 2005
Completion date	May 2017

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05023434` - A Study to Measure the Effect of Brain Stimulation on Hand Strength and Function in Patients With Brain Tumors
Terminated	`NCT01902771` - Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors	Phase 1
Completed	`NCT04114786` - 3D Printed Mask for GBM and Brain Mets	N/A
Recruiting	`NCT04367779` - Research of Biomarkers of Response to Proton Beam Therapy in Pediatric and Adult Patients.
Recruiting	`NCT06058988` - Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer	Phase 2
Completed	`NCT02911155` - Cancer and Other Disease Risks in U.S. Nuclear Medicine Technologists
Completed	`NCT02852655` - A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma	Phase 1
Completed	`NCT01650922` - Molecular Genetic Studies of Childhood Brain Tumors and Blood Samples	N/A
Completed	`NCT00329589` - A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and Neck, and Cervical Cancer Patients	Phase 1
Completed	`NCT00505141` - Urban Environmental Exposures and Childhood Cancer	N/A
Completed	`NCT00504660` - 6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients	Phase 2
Completed	`NCT00979810` - Image-Guided Stereotactic Biopsy of High Grade Gliomas	N/A
Recruiting	`NCT04899908` - Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases	Phase 2
Active, not recruiting	`NCT02851706` - Natural History of and Specimen Banking for People With Tumors of the Central Nervous System
Completed	`NCT02798406` - Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects	Phase 2
Completed	`NCT01012609` - External Beam Radiation Therapy and Cetuximab Followed by Irinotecan and Cetuximab for Children and Young Adults With Newly Diagnosed Diffuse Pontine Tumors and High-Grade Astrocytomas	Phase 2
Completed	`NCT00782756` - Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma	Phase 2
Terminated	`NCT03149575` - VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM	Phase 3
Completed	`NCT01974804` - Assessment of Early Treatment Response by Diffusion and Perfusion MRI in Patients With Brain Metastasis
Withdrawn	`NCT01320787` - 18-F-Fluoroacetate as PET Imaging Agent	Phase 1